There are currently 816 clinical trials in Washington, District Of Columbia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's National Medical Center, Medstar Georgetown University Hospital, MedStar Washington Hospital Center and Walter Reed Army Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Washington Hospital Center, Washington, District of Columbia
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Georgetown University Hospital Research, Washington, District of Columbia
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Phase 2b Study of Zagociguat in Patients With MELAS
NCT06402123
Recruiting
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Children's National, Washington, District of Columbia
Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Register for Updates
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Velocity Clinical Research - Washington DC, Washington, District of Columbia
Conditions: SARS-CoV2, COVID-19
Register for Updates
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
NCT05219110
Recruiting
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Gender:
ALL
Ages:
Between 9 months and 21 years
Trial Updated:
06/02/2025
Locations: Children's Research Institute, Washington, District of Columbia
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Register for Updates
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
Recruiting
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Acquired Hemophilia A
Register for Updates
Digoxin Medulloblastoma Study
NCT06701812
Recruiting
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
06/02/2025
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Washington, District of Columbia
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
NCT02203903
Recruiting
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Gender:
ALL
Ages:
Between 6 months and 80 years
Trial Updated:
05/29/2025
Locations: Childrens National Medical Center, Washington, District of Columbia
Conditions: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Register for Updates
Spinal Cord Injury Model Systems (SCIMS) - Education Module
NCT06003686
Recruiting
The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2025
Locations: MedStar National Rehabilitation Network, Washington, District of Columbia
Conditions: Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
Register for Updates
The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes
NCT06106035
Recruiting
The goal of this 16-week clinical trial is to assess the health benefits of a low-fat vegan diet on insulin sensitivity and glycemic control in type 2 diabetes. Participants will receive at no cost, study-related weekly nutrition education classes and one-on-one consultation with a registered dietitian.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Physicians Committee for Responsible Medicine, Washington, District of Columbia
Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese
Register for Updates